Ocular immunology and inflammation · 2010
Intravitreal methotrexate as adjunctive, palliative therapy in intraocular T-cell lymphoma.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wickremasinghe Sanjeewa S, Ojaimi Elvis, Lim Lyndell, Stawell Richard, McKelvie Penelope, Zamir Ehud
Аннотация
PURPOSE: To report on the rapid and sustained effect following injection of intravitreal methotrexate (IVTMTX) in intraocular T-cell lymphoma.
DESIGN: Report of 2 cases.
METHODS: A young male with natural killer/T-cell lymphoma presented with infiltrative nodular iridocyclitis and received a single IVTMTX. An elderly female with peripheral T-cell lymphoma presented with a hypopyon, infiltrative iridocyclitis, and choroidal effusions and received 3 IVTMTX over 4 months.
RESULTS: Both patients responded well after the first injection, with resolution of signs within 1 week and improvement in vision.
CONCLUSIONS: IVTMTX may be effective as a palliative, vision-restoring measure in patients with systemic T-cell lymphoma.
DESIGN: Report of 2 cases.
METHODS: A young male with natural killer/T-cell lymphoma presented with infiltrative nodular iridocyclitis and received a single IVTMTX. An elderly female with peripheral T-cell lymphoma presented with a hypopyon, infiltrative iridocyclitis, and choroidal effusions and received 3 IVTMTX over 4 months.
RESULTS: Both patients responded well after the first injection, with resolution of signs within 1 week and improvement in vision.
CONCLUSIONS: IVTMTX may be effective as a palliative, vision-restoring measure in patients with systemic T-cell lymphoma.